Form 8-K · Current Report · Filed 2025-11-04
Amgen Reports Strong Third Quarter 2025 Financial Results
Amgen Inc. reported its financial results for the third quarter of 2025, showing total revenues of $9.6 billion, a 12% increase from the same period in 2024. Product sales grew 12%, driven by 14% volume growth, partially offset by a 4% lower net selling price. GAAP earnings per share (EPS) increased 14% to $5.93, while non-GAAP EPS increased 1% to $5.64. The company generated $4.2 billion in free cash flow. Amgen also provided its full-year 2025 guidance, expecting total revenues between $35.8 billion and $36.6 billion, with GAAP EPS guidance of $13.76 to $14.60 and non-GAAP EPS guidance of $20.60 to $21.40.
- Filer
- Amgen Inc. AMGN · NASDAQ
- Filed
- Accession
- 0000318154-25-000070
- CIK
- 0000318154
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$296.30
Next session
+8.0%
Since filing
+30.0%
Latest close
$385.16
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from AMGN reporting the same item, with the next session's move:
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Never miss another AMGN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.